Chemours board member Bell resigns over disagreement on abortion, transgender benefits
Chemours Co
Bradley J. Bell resigned effective Jan 2, 2023, citing moral opposition to employee benefits coverage for transgender procedures, abortions, and travel for abortion services.
Bell served on the Compensation Committee and Nominating and Corporate Governance Committee.
In his resignation letter, Bell called the benefits 'morally and ethically wrong' and stated he could not reconcile his board role with his beliefs.
Bell is involved with women's medical clinics opposing abortion; he questioned whether the benefits reflect employee demand or a cultural statement.
On December 21, 2022, Bradley J. Bell notified the Company of his decision to resign as a member of the Board of Directors of the Company effective as of January 2, 2023.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 1.0
Bradley J. Bell resigned as Member of the Board of Directors at Chemours Co.
Action
resigned
Role
Member of the Board of Directors
Exact text from the filing
On December 21, 2022, Bradley J. Bell notified the Company of his decision to resign as a member of the Board of Directors of the Company effective as of January 2, 2023.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.